MedBulletinsAura Celeste
Nephrology

Monthly nephrology bulletin — September 29, 2026

🎧 Listen to this issueAudio newscast · 5:57 min

Monthly nephrology bulletin covering verified advances from August 30 to September 29, 2026. Note for the month: it was a strong month for regulatory decisions (two FDA approvals) and glomerular disease, and a thin one for dialysis and vascular access, where no new verifiable trial was found; that section includes only what exists and is not padded. Searches were run in English, Spanish, Portuguese, Chinese, Japanese, Korean, Russian and Turkish; the yield from Asian and Russian sources was scarce this month and is flagged where relevant.

Chronic kidney disease and kidney protection

1. FDA approves finerenone for CKD associated with type 1 diabetes

[Regulatory FDA] [United States / Germany]
The approval (September 16–17) rests on FINE-ONE, a phase 3, randomized, double-blind, placebo-controlled trial of 242 adults with CKD and type 1 diabetes (NEJM 2026;394:947-957). The primary endpoint, change in urine albumin-to-creatinine ratio, was −22% at 3 months and −28% at 6 months versus placebo (ratio of means 0.72; 95% CI 0.60–0.86; P = 0.0001). Hyperkalemia occurred in 10.1% vs 3.3%, with discontinuation for hyperkalemia in 1.7% vs 0%.
Why it matters: it is the first new therapy for this population in more than 30 years, but the endpoint is a surrogate, follow-up is 6 months and the trial was funded by Bayer; in the Dominican Republic, availability and price of finerenone remain the real barrier, and potassium monitoring is mandatory.
https://doi.org/10.1056/NEJMoa2512854
https://www.businesswire.com/news/home/20260916814212/en/Bayers-KERENDIA-finerenone-Receives-FDA-Approval-as-the-First-New-Treatment-in-30-Years-for-Adults-with-Chronic-Kidney-Disease-CKD-and-Type-1-Diabetes

2. EASi-KIDNEY: vicadrostat plus empagliflozin stopped for futility

[Industry] [Germany / United Kingdom]
On September 15 Boehringer Ingelheim announced the discontinuation of the phase 3 EASi-KIDNEY trial (with the University of Oxford), which compared the aldosterone synthase inhibitor vicadrostat plus empagliflozin against empagliflozin alone in adults with CKD. Following the independent data monitoring committee's recommendation, the company concluded that accumulating data "did not support a meaningful expectation of clinical benefit" on the primary composite endpoint; the release gives no components, numbers or safety findings. The program's other three phase 3 trials continue.
Why it matters: only the headline is available, with no numbers and no peer review, but the lesson is relevant: adding a fourth pillar on top of an SGLT2 inhibitor does not guarantee benefit, and it tempers expectations for this class in CKD.
https://www.boehringer-ingelheim.com/human-health/boehringer-provides-update-easi-kidney-trial

3. Network meta-analysis: SGLT2 inhibitors, semaglutide and finerenone in diabetic kidney disease

[Meta-analysis] [China]
Bayesian network meta-analysis (Frontiers in Pharmacology, September 24) of six trial-level datasets with 20,521 participants with type 2 diabetes and CKD. Versus placebo, the composite kidney outcome was reduced by SGLT2 inhibitors (HR 0.70; 95% CrI 0.64–0.76), semaglutide (HR 0.76; 0.66–0.88) and finerenone (HR 0.84; 0.77–0.92).
Why it matters: these are indirect comparisons from few trials with heterogeneous outcome definitions, so they do not replace a head-to-head trial; publicly funded in China. It reinforces the practical hierarchy: SGLT2 inhibitor first, the other two as add-ons. (Source in English, Beijing group.)
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1882227/full

Dialysis and vascular access

No new randomized trial or verifiable regulatory approval in hemodialysis, peritoneal dialysis or vascular access was identified within the window this month. No other item is included in this section.

Kidney transplantation and immunology

4. Gene-edited pig kidney as a bridge to human transplantation

[Publication] [United States]
Mass General Brigham published in The Lancet (press release September 3) the first documented case of porcine kidney xenotransplantation as a bridge to allotransplantation. A 66-year-old man received the pig kidney in January 2025, remained dialysis-free for 271 days, overcame early T-cell-mediated rejection and, after immunosuppression was reduced because of an infection, the graft developed microvascular injury and failed; in January 2026 he received a deceased-donor kidney with immediate function and no sensitization.
Why it matters: it is a single case under FDA expanded access, funded by Massachusetts General Hospital and eGenesis, but it shows that a xenograft can buy time without compromising the subsequent transplant, particularly relevant where waiting lists are long and donation is scarce.
https://doi.org/10.1016/S0140-6736(26)01295-X
https://news.massgeneralbrigham.org/en/pig-kidney-xenotransplant-bridge-to-human-transplant

5. Atacicept in IgA nephropathy: final 104-week data from ORIGIN 3

[Industry] [United States, multicenter]
On September 15 Vera Therapeutics reported the final results of the phase 3 ORIGIN 3 trial (n = 428, randomized 1:1, double-blind, atacicept 150 mg subcutaneous weekly versus placebo). eGFR slope over 104 weeks −0.6 vs −5.6 mL/min/1.73 m² per year (P < 0.0001); eGFR change at 52 weeks −0.1 vs −5.7 (difference 5.6; 95% CI 3.7–7.5); composite kidney progression 11 vs 38 events (HR 0.24; 95% CI 0.12–0.48).
Why it matters: it is a manufacturer-funded press release without peer review; if confirmed, the effect on eGFR slope is large, and the application for full approval is planned for the fourth quarter of 2026.
https://www.hcplive.com/view/atacicept-cuts-igan-progression-risk-76-in-origin-3-final-data

Acute kidney injury and critical care, pediatric nephrology and genetics

6. FDA approves obinutuzumab for childhood-onset idiopathic nephrotic syndrome

[Regulatory FDA] [United States / Switzerland]
Approved September 25 to reduce the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome in complete remission. In the phase 3 INShore trial versus mycophenolate mofetil, complete remission at week 52 was 95% with obinutuzumab vs 73%, according to Genentech.
Why it matters: a manufacturer trial (Roche/Genentech) and the release gives no sample size or detailed design, but according to Genentech it is the first therapy approved for idiopathic nephrotic syndrome in 70 years and offers an option with less steroid exposure; the cost of the biologic will limit its use in our setting.
https://www.gene.com/media/statements/ps_092526

7. Inaxaplin in APOL1-mediated kidney disease: phase 2b AMPLIFIED

[Industry] [United States]
Vertex reported on September 22 results of the single-arm phase 2b study of inaxaplin 45 mg daily for 13 weeks in 41 patients. In the cohort without diabetes (albuminuria 0.1–0.42 g/g) UACR fell 42.7% (95% CI −58.3 to −21.1); in the cohort with type 2 diabetes it fell 17.3% (95% CI −36.3 to +7.2), not significant. No related serious adverse events.
Why it matters: no control group, very few patients, 13 weeks and a surrogate endpoint; still, it is the first gene-specific target in a disease that mostly affects people of African ancestry, with potentially high prevalence in the Caribbean. Phase 3 (AMPLITUDE) interim analysis data are expected in early 2027.
https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study

Cross-cutting

8. ESC/ERA guideline on cardiovascular disease in CKD and the ASN glomerular disease compendium

[Guideline] [Europe / United States] [Outside the period: August 29]
The European Society of Cardiology and the European Renal Association published on August 29 (European Heart Journal, ESC Congress) the first joint guideline on cardiovascular disease in CKD, with the "STAMP" framework. Separately, the American Society of Nephrology launched the compendium of its Glomerular Diseases Collaborative (GD-C), a platform on ANCA vasculitis, IgA nephropathy, lupus nephritis, C3 glomerulopathy and membranous nephropathy, with referral pathways, landmark trials and newer therapies.
Why it matters: both are consensus documents rather than new evidence; the European guideline finally sets a shared cardio-kidney standard and the compendium is a useful reference for residents.
https://www.hcplive.com/view/faq-understanding-new-esc-era-guideline-on-cardiovascular-disease-and-chronic-kidney-disease
https://www.hcplive.com/view/how-the-asn-s-gd-c-compendium-aims-to-unify-glomerular-disease-care

9. Latin America and Asia: Brazilian congress and China's essential medicines list

[Congress] [Brazil / China]
The Brazilian Society of Nephrology held the XXXIII Brazilian Congress of Nephrology on September 16–19 in Belo Horizonte (Minascentro). In China, the 2026 National Essential Medicines List (794 drugs, 109 more than in 2018), which adds finerenone, roxadustat and sevelamer, took effect on September 1. No verifiable trials or approvals were found within the window from Japan, Korea, India, Russia or the Middle East.
Why it matters: the Chinese list is health policy, not evidence, but it shows how large systems bring the pillars of kidney protection into public access, still pending in several countries of the region. (Sources in Portuguese and Chinese.)
https://sbn.org.br/category/congresso-brasileiro-de-nefrologia-2026/
https://www.nephro-online.com/index/article/detail?id=11374

Upcoming meetings and dates

ASN Kidney Week 2026: October 22–25 (early programs October 21), Denver, USA. https://www.asn-online.org/education/kidneyweek/2026/important-dates.aspx

56th National Congress of the Spanish Society of Nephrology (SEN): November 5–7, Murcia, Spain. https://www.congresosen.com/2026

SLANH: webinar "Current challenges in CKD and its complications," September 30, 8:00 pm (Panama time). No SLANH congress in 2026; the next is in 2027. https://slanh.net/

Get every issue by email

Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.